Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China

Fineline Cube Nov 27, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...

Company Drug

Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation

Fineline Cube Nov 27, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...

Company Medical Device

Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial

Fineline Cube Nov 27, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Company Deals

Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee

Fineline Cube Nov 27, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company

FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site

Fineline Cube Nov 27, 2023

The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...

Company Drug

Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules

Fineline Cube Nov 27, 2023

Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...

Policy / Regulatory R&D

China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development

Fineline Cube Nov 27, 2023

China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...

Company Legal / IP

AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market

Fineline Cube Nov 27, 2023

AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...

Company Drug

Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia

Fineline Cube Nov 27, 2023

Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080

Fineline Cube Nov 24, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...

Company Drug

Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study

Fineline Cube Nov 24, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...

Company Deals

Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China

Fineline Cube Nov 24, 2023

China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...

Company

Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany

Fineline Cube Nov 24, 2023

Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German...

Company

Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility

Fineline Cube Nov 24, 2023

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...

Company Deals

Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development

Fineline Cube Nov 24, 2023

China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...

Policy / Regulatory

European Commission Proposes Overhaul of Pharmaceutical Legislation

Fineline Cube Nov 24, 2023

The European Commission (EC) is advancing an update to Europe’s 20-year-old pharmaceutical legislation, with the...

Company Drug

Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval

Fineline Cube Nov 24, 2023

Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received...

Posts pagination

1 … 491 492 493 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.